# Brodalumab

## Lumicef 210mg/1.5mL inj

##### 臨採

| TAH Drug Code      | [ILUMI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ILUMI)                                                                                                                                                                                                                                                                                                           |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderate to severe plaque psoriasis, pustular psoriasis.                                                                                                                                                                                                                                                                                                                         |
| Dosing             | SC, 210 mg at weeks 0, 1, and 2, followed by 210 mg once every 2 weeks.                                                                                                                                                                                                                                                                                                          |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Crohn disease, Clinically significant hypersensitivity to brodalumab or any component of the formulation.                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common Gastrointestinal: Diarrhea (2.2% ) Immunologic: Infectious disease (25.4% ), Mycosis (1.8% to 2.4% ) Musculoskeletal: Arthralgia (4.7% ) Neurologic: Headache (4.3% ) Respiratory: Pain in throat (2.1% ) Other: Fatigue (2.6% ) Serious Hematologic: Neutropenia, Grade 3 or greater (0.5% ) Neurologic: Cryptococcal meningitis Psychiatric: Suicidal thoughts, Suicide |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                    |

